Reimbursement of anti-obesity drugs: a minimum cost for Health Insurance?

The coverage of Wegovy and Mounjaro, used in the treatment of obesity from this Monday, June 15, could ultimately prove less expensive than expected for public accounts. A winning strategy for the State and the labs.